Edit
Samumed
http://www.samumed.com/Last activity: 15.08.2019
Active - Reference to Biosplice Therapeutics
Samumed is a life science company specializing in small molecule drugs that selectively activate or inhibit the Wnt pathway toward treatment of oncological and degenerative diseases.
Employees: 201-500
Total raised: $438M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Vickers Ve... | vickersven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.08.2018 | Series A | $438M | - |
Mentions in press and media 11
| Date | Title | Description |
| 15.08.2019 | In conversation with Samumed CEO Osman Kibar: Drugging Wnt, restoring youth and unconventional capital | Founded in 2008, Samumed has spent most of its lifetime working under the radar. It came out of the shadows in 2016 with a war chest of $220 million drawn from investors including Ikea’s private venture arm and some very wealthy individuals... |
| 25.10.2018 | Mixed data doesn't stop this biotech unicorn from plotting a looming PhIII showdown | Samumed has often found it easier to come up with lots more investor cash than consistently positive clinical data. And that odd juxtaposition has never been more apparent than in its latest readout for their lead drug... |
| 24.10.2018 | Samumed, a $12 billion startup that wants to cure baldness and smooth out your wrinkles, just released promising data on its lead drug to treat osteoarthritis | Diana Yukari/Business Insider; photos courtesy Samumed Samumed CEO Osman Kibar, CFO Cevdet Samikoglu, and chief medical officer Yusuf Yazici Advertisement $12 billion biotech Samumed on Wednesday is presenting data from a clinical trial loo... |
| 07.08.2018 | Samumed Raises $438M | San Diego-based Samumed, a biopharmaceuticals firm focused on treatments for Alzheimer's and other diseases, has raised a huge, $438M funding round, the company said on Monday. Source of the funding was not announced. Samumed says it has no... |
| 07.08.2018 | Samumed raises $438 million to fund regenerative medicine development | The company plans to use funding to advance lead candidate, SM04690, in knee osteoarthritis, while also advancing other drug candidates and expanding its portfolio, the spokesperson said. According to Samumed’s pipeline page, the small-mole... |
| 06.08.2018 | Samumed Closes $438M Series A-6 | SAN DIEGO, CA, Samumed announced today that it has closed its A-6 Round of equity issuance with $438 million. >> Click here for more funding data on Samumed >> To export Samumed funding data to PDF and Excel, click here S... |
| 06.08.2018 | Samumed Closes on $438M in Equity Financing | Samumed, a San Diego, CA-based small-molecule drug platform, has secured $438m in funding. The investors were not disclosed. THE PRESS RELEASE Samumed Closes on $438 Million in Equity Financing SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) — Sa... |
| 06.08.2018 | What's bigger than a unicorn? Samumed stuns yet again as anti-aging pipeline draws $438M at $12B valuation | Samumed came out with a bang a couple years ago, when it boldly announced a couple of anti-aging programs and a $12 billion valuation. The San Diego company, which operated in stealth through much of its first decade, had n... |
| 06.08.2018 | Term Sheet — Monday, August 6 | GOBBLED Nope, meal kits are still not over. Neither are the grocery wars. Paid Content Securing the enterprise without boundaries From ExtraHop Four months after Walmart introduced its own prepared meal offering, the retail behemoth has now... |
| 06.08.2018 | Samumed, San Diego Biotech Developing Regenerative Drugs, Announces $438M Financing Round | San Diego-based biotech company Samumed LLC announced Aug. 6 it had raised $438 million, bringing the total money it has raised to more than $650 million. Samumed, founded in 2008 by CEO Osman Kibar, is developing medicines it says have the... |
Show more